ESMO 2024: Targeting the Treatment Challenges of Small Cell Lung Cancer - Episode 5
Defining Platinum Sensitivity in SCLC
Panelists discuss how the definition of platinum sensitivity in extensive-stage small cell lung cancer may still rely on the 90-day criterion, while also exploring other factors contributing to treatment resistance, alongside an examination of tarlatamab’'s unique mechanism as a bispecific T-cell engager and its potential as a subsequent therapy after platinum-based chemotherapy.
Video content above is prompted by the following:
1. Dr Sen: At the community practice level, does 90 days continue to define platinum sensitivity status among patients with extensive-stage small cell lung cancer (SCLC)?
- What other factors contribute to the definition of treatment resistance in this patient subgroup?
2. Dr Iams: Please briefly discuss the unique mechanism of action of tarlatamab, a bispecific T-cell engager, and its treatment potential as subsequent therapy for SCLC that has progressed after platinum-based chemotherapy.
Related Content:
